Entering text into the input field will update the search result below

Cybin gets FDA green light to begin clinical trial of psilocybin candidate for depression

Jun. 27, 2022 8:40 AM ETCybin Inc. (CYBN) StockBy: Jonathan Block, SA News Editor

Psilocybin and Magic Mushrooms

24K-Production/iStock via Getty Images

  • The U.S. FDA has granted Investigational New Drug application clearance to Cybin's (NYSE:CYBN) CYB003, an analog of the psychedelic compound psilocybin for major depressive disorder.
  • Cybin can now begin a phase 1/2a double-blind, placebo-controlled trial. In it, Participants will receive two administrations (placebo/active and active/active) and response will be evaluated at week 3 (after first dose) and at Week 6 (after second dose).
  • The company expects to have an interim pharmacokinetic and safety data readout in Q4.
  • Check out some of the other companies that are evaluating psychedelics as therapies.

Recommended For You

More Trending News

About CYBN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CYBN--
Cybin Inc.